Guardant Health and Verana Health to Leverage 95M-Patient Real-World Data
Guardant Health is partnering with Verana Health to integrate its clinicogenomic testing data with Verana’s curated EHR datasets, expanding analysis across lung, breast and colorectal cancers and more than 95 million patient records. The collaboration targets NMIBC biomarker validation and will serve 17 of the top 20 global biopharma companies.
1. Partnership Overview
Guardant Health and Verana Health will combine Guardant’s longitudinal clinicogenomic testing datasets with Verana’s regulatory-grade, therapeutic-specific EHR data from leading medical societies and centers to enable deeper insights into molecular biomarkers, treatment decisions and real-world clinical outcomes.
2. Data Expansion Across Cancer Types
The integrated dataset spans all disease stages—from initial tumor profiling through recurrence and therapy response monitoring—and extends Verana’s registry to include solid tumors in lung, breast and colorectal cancers, covering over 95 million patients and more than 20,000 contributing clinicians.
3. Biopharma Implications
By focusing on NMIBC biomarker validation and optimizing BCG therapy escalation, the alliance aims to accelerate targeted therapy development for 17 of the top 20 global biopharma companies, enhance personalized cancer treatment strategies and streamline regulatory submissions.